Discover more than 2,000 medical and toxicological tests and POCT solutions
Please note: The prices shown are basic list prices. Your individual prices will be displayed after you have logged in to the shop. Your personal customer advisors can add them at any time.
The NADAL® COVID-19 Ag+Influenza A/B plus Test is a lateral flow chromatographic immunoassay for the simultaneous qualitative detection of SARS-CoV-2, as well as influenza virus type A and B viral nucleoprotein antigens in human nasal, nasopharyngeal or oropharyngeal specimens. This test is intended for use as an aid in the diagnosis of infections with SARS-CoV-2 as well as influenza virus type A and B. Note that the concentration of viral nucleoprotein antigens may vary in the course of the disease and might fall below the detection limit of the test. The potential infectiousness of test subjects cannot be ruled out based on negative test results. The test procedure is not automated and requires no special training or qualification. The NADAL® COVID-19 Ag+Influenza A/B plus Test is designed for professional use only.
COVID-19 (Coronavirus disease) is an infectious disease caused by the recently discovered coronavirus SARS-CoV-2. The most common symptoms of COVID-19 are a fever, dry cough, fatigue, sputum production, shortness of breath, a sore throat and headaches. Some patients may have myalgia, chills, nausea, nasal congestion and diarrhoea. These symptoms begin gradually and are mild in most cases. Some individuals become infected but do not develop any symptoms and do not feel unwell. Most people (about 80%) recover from the disease without special treatment. Approximately one in six people who get infected with COVID-19 become seriously ill and develop difficulty breathing. Elderly people and those with preexisting conditions such as high blood pressure, heart problems or diabetes, are more likely to develop serious illness. COVID-19 is transmitted via respiratory droplets that are exhaled by infected people via coughing, sneezing or talking. Most estimates of the incubation period for COVID-19 range from 1 to 14 days, during which people might already be infectious without showing symptoms of disease.
Influenza is a highly contagious viral infection of the upper respiratory tract which is characterised by antigen variability, seasonality and its impact on the general population. Of the two main types (A and B) of influenza viruses, influenza A subtypes are differentiated by the antigen variability of surface glycoproteins (haemagglutinin and neuraminidase). The influenza A virus is the most prevalent and is associated with the most serious epidemics. Influenza can cause severe complications such as bronchitis or pneumonia, particularly in children, the elderly or those with chronic respiratory diseases. However, it most commonly occurs as a mild viral infection transmitted by respiratory secretions through sneezing or coughing. There are many other viral infections that can mimic influenza symptoms, making laboratory tests necessary to distinguish it from other acute respiratory infections.
